040-000-316 Docetaxel, CAS 114977-28-5

SKU: 040-000-316 Category:
Get A Quote

  I would like to join the mailing list to receive updates from Stanford Chemicals.
*: e-mail address with your company's domain name is preferred. Otherwise, we may not be able to process your inquiry.

Synonyms DTX, DXL, Taxotere
Keywords Antibiotics, non-small-cell lung cancer, ‎taxol, paclitaxel, cancer
Related products Paclitaxel (Taxol), Taxus Chinensis Extract


Docetaxel Specifications

Product Name Docetaxel
CAS Registry Number 114977-28-5
Molecular Formula C43H53NO14
Molecular Weight 807.55 g/mol
Purity >98 %
Package 1kg-25kg
Shelf life 2 years
Functions It can treat breast, lung, prostate, stomach, and head and neck cancer.

Docetaxel Description

Docetaxel (docetaxel) has the same effect as paclitaxel (PTX). It is a M-cycle specific drug that promotes the polymerization of tubules into stable microtubules and inhibits their aggregation, thereby significantly reducing the number of tubules. And can destroy the microtube network structure. In vitro experiments show that it has a cytotoxic effect on a variety of mouse and human tumor cell lines, with a broader anti-tumor spectrum than PTX.

Docetaxel is a taxoid antineoplastic agent used in the treatment of various cancers, such as locally advanced or metastatic breast cancer, metastatic prostate cancer, gastric adenocarcinoma, and head and neck cancer.


Docetaxel Applications

  • Pharmaceutical ingredients of anti-cancer drugs.


  1. Mahon, K.L., Henshall, S.M., Sutherland, R.L., et al. Pathways of chemotherapy resistance in castration-resistant prostate cancer. Endocrine-Related Cancer 18, R103-R123 (2011).
  2. Bissery, M.C., Guenard, D., Gueritte-Voegelein, F., et al. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Research 51, 4845-4852 (1991).
  3. Yao, X., Hosenpud, J., Chitambar, C.R., et al. A phase II study of concurrent docetaxel, epirubicin and cyclophospha-mide as a neoadjuvant chemotherapy regimen in patients with locally advanced breast cancer. Journal of Cancer 3, 145-151 (2012).